Inotuzumab-Ozogamicin induces remissions and enables allogeneic SCT in patients with Blinatumomab-refractory B-precursor acute lymphoblastic leukemia

被引：0
|
作者：
Buecklein, Veit [1 ,2 ]
Fraccaroli, Alessia [1 ]
Prevalsek, Dusan [1 ]
Haebe, Sarah [1 ]
Schulz, Christoph [1 ]
Zoellner, Anna-Katharina [1 ]
Spiekermann, Karsten [1 ]
Subklewe, Marion [1 ,2 ]
Tischer, Johanna [1 ]
机构：
[1] Univ Munich, Univ Hosp, Dept Med 3, Munich, Germany
[2] Univ Munich, Gene Ctr, Translat Canc Immunol, Munich, Germany
来源：
BONE MARROW TRANSPLANTATION | 2018年 / 53卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P033
引用
收藏
页码：170 / 171
页数：2
相关论文
共 50 条
  • [1] Use of inotuzumab-ozogamicin in a child with Down syndrome and refractory B-cell precursor acute lymphoblastic leukemia
    Murillo, Laura
    Luis Dapena, Jose
    Velasco, Pablo
    Diaz de Heredia, Cristina
    PEDIATRIC BLOOD & CANCER, 2019, 66 (04)
  • [2] Immunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).
    Schub, Andrea
    Naegele, Virginie
    Zugmaier, Gerhard
    Brandl, Christian
    Hijazi, Youssef
    Topp, Max S.
    Kufer, Peter
    Wolf, Andreas
    Klinger, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
    Topp, M. S.
    Stelljes, M.
    Zugmaier, G.
    Barnette, P.
    Heffner, L. T., Jr.
    Trippett, T.
    Duell, J.
    Bargou, R. C.
    Holland, C.
    Benjamin, J. E.
    Klinger, M.
    Litzow, M. R.
    LEUKEMIA, 2018, 32 (02) : 562 - 565
  • [4] Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
    M S Topp
    M Stelljes
    G Zugmaier
    P Barnette
    L T Heffner
    T Trippett
    J Duell
    R C Bargou
    C Holland
    J E Benjamin
    M Klinger
    M R Litzow
    Leukemia, 2018, 32 : 562 - 565
  • [5] Immunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)
    Schub, A.
    Naegele, V
    Zugmaier, G.
    Brandl, C.
    Hijazi, Y.
    Topp, M. S.
    Kufer, P.
    Wolf, A.
    Klinger, M.
    ONKOLOGIE, 2013, 36 : 183 - 183
  • [6] Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
    Thomas E. Delea
    Xinke Zhang
    Jordan Amdahl
    Diana Boyko
    Franziska Dirnberger
    Marco Campioni
    Ze Cong
    PharmacoEconomics, 2019, 37 : 1177 - 1193
  • [7] Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
    Delea, Thomas E.
    Zhang, Xinke
    Amdahl, Jordan
    Boyko, Diana
    Dirnberger, Franziska
    Campioni, Marco
    Cong, Ze
    PHARMACOECONOMICS, 2019, 37 (09) : 1177 - 1193
  • [8] Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Irina Proskorovsky
    Yun Su
    Kyle Fahrbach
    Erik Vandendries
    Véronique Pagé
    Uchenna Onyekwere
    Yunyang Wang
    Joseph C. Cappelleri
    Matthias Stelljes
    Advances in Therapy, 2019, 36 : 2147 - 2160
  • [9] Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Proskorovsky, Irina
    Su, Yun
    Fahrbach, Kyle
    Vandendries, Erik
    Page, Veronique
    Onyekwere, Uchenna
    Wang, Yunyang
    Cappelleri, Joseph C.
    Stelljes, Matthias
    ADVANCES IN THERAPY, 2019, 36 (08) : 2147 - 2160
  • [10] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
    Bhojwani, Deepa
    Sposto, Richard
    Shah, Nirali N.
    Rodriguez, Vilmarie
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    O'Brien, Maureen M.
    McNeer, Jennifer L.
    Quereshi, Amrana
    Cabannes, Aurelie
    Schlegel, Paul
    Rossig, Claudia
    Dalla-Pozza, Luciano
    August, Keith
    Alexander, Sarah
    Bourquin, Jean-Pierre
    Zwaan, Michel
    Raetz, Elizabeth A.
    Loh, Mignon L.
    Rheingold, Susan R.
    LEUKEMIA, 2019, 33 (04) : 884 - 892
12345